The activation of butyrate-mediated GPR43 attenuates renal inflammation, reduces uremic toxin levels, such as those of p-cresyl sulfate and indoxyl-sulfate, and delays CKD progression [46]. The gene discussed is FFAR2; the disease is chronic kidney disease.